论文部分内容阅读
目的对131Ⅰ治疗巨大与非巨大甲状腺肿性Graves甲亢的疗效进行比较。方法 131Ⅰ治疗甲状腺质量大于70g的甲亢患者90例作为观察组;经131Ⅰ治疗甲状腺质量小于70g的甲亢患者90例作为参照组。比较两组甲状腺功能减退的情况以及一次治愈率和总治愈率。结果观察组一次治愈率为57.78%,参照组为38.89%,比较差异具有统计学意义(P<0.05);观察组的总治愈率为92.22%,参照组为87.78%,比较差异无统计学意义(P>0.05);同时,观察组患者的早发加减发生率为4.44%,参照组为6.67%,比较差异无统计学意义(P>0.05)。结论采用131Ⅰ进行治疗巨大甲状腺肿性Graves甲亢,其总治愈率以及早发加减的发生率同非巨大性甲状腺肿性Graves甲亢具有相近性。同时能够得到一定的安全性,降低不良反应的发生率,从而提高患者的生活质量,值得在临床实践治疗中广泛应用。
Objective To compare the curative effect of 131 Ⅰ treatment with non-giant goiter and Graves hyperthyroidism. Ninety cases of hyperthyroidism with thyroid mass greater than 70g were treated by 131 Ⅰ as observation group and 90 cases of hyperthyroidism treated by 131Ⅰ with thyroid mass less than 70g as reference group. Hypothyroidism was compared between the two groups as well as a cure rate and total cure rate. Results The primary cure rate was 57.78% in the observation group and 38.89% in the reference group, with statistical significance (P <0.05). The total cure rate in the observation group was 92.22% and that in the reference group was 87.78%, with no significant difference (P> 0.05). In the meantime, the incidence of early onset and decrease of the observation group was 4.44% and that of the reference group was 6.67%, with no significant difference (P> 0.05). Conclusions 131I treatment of giant goiter Graves hyperthyroidism, the total cure rate and the incidence of early onset and reduction with non-giant goiter Graves hyperthyroidism are similar. At the same time be able to get a certain degree of safety and reduce the incidence of adverse reactions, thereby improving the quality of life of patients, it is worth in the clinical practice of treatment is widely used.